At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 202 enrolled
Drug / intervention
Olaparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation
In Brief
A Phase 4 clinical trial evaluating Olaparib for Ovarian Cancer and Breast Cancer. Completed, enrolled 202 participants across 16 sites.
Detailed Summary
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA (BReast CAncer gene) 1/2 Mutation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Breast Cancer
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionSep 2022
TodayJul 2026
First PostedApr 1, 2020
Enrollment StartMay 25, 2020
Primary CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.3 years ago
Interventions
Olaparibdrug
Tablet